ProCE Banner Activity

Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Podcast Episodes
Listen to Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, as they provide their clinical insights into dosing of key later-line treatment options for patients with mCRC.

Released: October 21, 2021

Expiration: October 20, 2022

Share

Faculty

Kanwal Raghav

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rachel Riechelmann

Rachel Riechelmann, MD, PhD

Director, Clinical Oncology
AC Camargo Cancer Center
Sao Paulo, Brazil

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD, has disclosed that he has received funds for research support from Bayer, Daiichi, Medimmune, Merck, and Roche; consulting fess from Bayer and Daiichi; and fees for non-CME/CE services from Daiichi.

Rachel Riechelmann, MD, PhD

Director, Clinical Oncology
AC Camargo Cancer Center
Sao Paulo, Brazil

Rachel Riechelmann, MD, PhD, has disclosed that she has received funds for research support from Amgen and consulting fees from Amgen, Bayer, MSD, and Novartis.